Last reviewed · How we verify
RD13-02 cell infusion
At a glance
| Generic name | RD13-02 cell infusion |
|---|---|
| Also known as | universal CD7 CAR-T cells |
| Sponsor | Nanjing Bioheng Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies (EARLY_PHASE1)
- A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM (EARLY_PHASE1)
- CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia (PHASE1)
- RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies (PHASE1)
- RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies (EARLY_PHASE1)
- RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL (EARLY_PHASE1)
- CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL (EARLY_PHASE1)
- Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RD13-02 cell infusion CI brief — competitive landscape report
- RD13-02 cell infusion updates RSS · CI watch RSS
- Nanjing Bioheng Biotech Co., Ltd. portfolio CI